API | lmp-specific cytotoxic t-lymphocytes

lmp-specific cytotoxic t-lymphocytes Report issue

Cell therapy Experimental

AACT

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Latent membrane protein 1 (Human herpesvirus 4 (strain B95-8)) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes | allogeneic lmp specific cytotoxic t-lymphocyte | lmp1/2-specific cytotoxic t lymphocytes | lmp1- and lmp2- specific cytotoxic t-lymphocytes | lmp1 specific cytotoxic t-lymphocytes | lmp2-specific cytotoxic t-lymphocytes | lmp-specific cytotoxic t-lymphocytes

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Epstein-Barr Virus Infections (Phase 1)

Hodgkin Disease (Phase 2)

Leiomyosarcoma (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoproliferative Disorders (Phase 2)

Nasopharyngeal Carcinoma (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue